Skip to Content

News & Events

Press Releases

Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryJan 11, 2017	Merck KGaA, Darmstadt, Germany Licenses Four Oncology Research and Development Programs from Vertex -Merck KGaA, Darmstadt, Germany licenses two promising clinical-stage programs targeting DNA damage and repair, and two novel pre-clinical programs- -Vertex receives upfront payment of $230 million plus royalties on future sales- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated Other	View HTML Merck KGaA, Darmstadt, Germany Licenses Four Oncology Research and Development Programs from Vertex 21 KB
Toggle SummaryDec 21, 2006	Merck and Vertex Announce Start of Pivotal Phase 2 Clinical Trial for Investigational Aurora Kinase Inhibitor MK-0457 (VX-680) in Patients with Treatment-Resistant Forms of Advanced Leukemias - Vertex Earns $25 Million Milestone Payment Upon Start of Patient Dosing - Other	View HTML Merck and Vertex Announce Start of Pivotal Phase 2 Clinical Trial for Investigational Aurora Kinase Inhibitor MK-0457 (VX-680) in Patients with Treatment-Resistant Forms of Advanced Leukemias 17.1 KB
Toggle SummaryDec 11, 2006	Merck and Vertex Announce Phase I Results for Investigational Aurora Kinase Inhibitor MK-0457 (VX-680); Compound Showed Activity in Patients with Treatment-Resistant Forms of Advanced Leukemias and Myeloproliferative Disorders - Additional Preclinical Combination Studies Suggest Synergistic Activity of MK-0457 and Other Kinase Inhibitors - Other	View HTML Merck and Vertex Announce Phase I Results for Investigational Aurora Kinase Inhibitor MK-0457 (VX-680); Compound Showed Activity in Patients with Treatment-Resistant Forms of Advanced Leukemias and Myeloproliferative Disorders 19.3 KB
Toggle SummaryJun 22, 2004	Merck & Co., Inc. and Vertex Announce Broad Collaboration to Develop and Commercialize VX-680, a Novel Compound for the Treatment of Cancer Merck & Co., Inc. and Vertex Announce Broad Collaboration to Develop and Commercialize VX-680, a Novel Compound for the Treatment of Cancer Whitehouse Station, NJ and Cambridge, MA, June 22, 2004 -- Merck & Co., Inc. (NYSE: MRK) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today Other	View HTML Merck & Co., Inc. and Vertex Announce Broad Collaboration to Develop and Commercialize VX-680, a Novel Compound for the Treatment of Cancer 17.5 KB
Toggle SummaryJul 26, 2005	Long-Term Safety Data of Lexiva/r in HIV Patients Co-Infected with Hepatitis - Combination of Lexiva/r and Truvada Evaluated - General Business	View HTML Long-Term Safety Data of Lexiva/r in HIV Patients Co-Infected with Hepatitis 15.3 KB
Toggle SummaryMay 15, 2024	Jennifer Schneider Elected to Vertex Board of Directors BOSTON --(BUSINESS WIRE)--May 15, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Jennifer Schneider , M.D., M.S., has been elected to its Board of Directors as an independent director. Dr. Schneider has more than two decades of experience in the health care industry	View HTML PDF Version
Toggle SummaryJul 7, 2009	Jeffrey Leiden M.D., Ph.D. and Dennis Winger Join Vertex Pharmaceuticals' Board of Directors CAMBRIDGE, Mass., Jul 07, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that Jeffrey Leiden, M.D., Ph.D. and Dennis Winger joined its board of directors. "Jeff and Dennis add tremendous medical and biomedical business perspective to our board. Webcasts	View HTML Jeffrey Leiden M.D., Ph.D. and Dennis Winger Join Vertex Pharmaceuticals' Board of Directors 10.5 KB
Toggle SummaryApr 14, 2007	Interim Results Presented at EASL from PROVE 1 Clinical Trial of Investigational Drug Telaprevir in Patients with Genotype 1 Hepatitis C -- PROVE 1 data support potential to shorten treatment duration in treatment-naive, genotype 1 HCV patients -- HCV	View HTML Interim Results Presented at EASL from PROVE 1 Clinical Trial of Investigational Drug Telaprevir in Patients with Genotype 1 Hepatitis C 22.5 KB
Toggle SummaryOct 28, 2009	Interim Results from Study 107 Highlight the Potential Role of Telaprevir-Based Regimens in HCV Patients Who Failed Prior Treatment <ul><li class="bwlistitemmarginbottom"><i><b>57% of prior treatment null responder patients achieved an SVR with a 48-week telaprevir-based regimen</b></i></li><li class="bwlistitemmarginbottom"><i><b>90% of prior treatment relapsers and 55% of prior treatment partial responders achieved an SVR with 24-week or 48-week telaprevir-based regimens</b></i></li><li class="bwlistitemmarginbottom"><i><b>Results provide further support for the ongoing Phase 3 registration study, REALIZE, in treatment-failure patients</b></i></li></ul> Webcasts	View HTML Interim Results from Study 107 Highlight the Potential Role of Telaprevir-Based Regimens in HCV Patients Who Failed Prior Treatment 23.6 KB
Toggle SummaryMar 31, 2011	Interim Phase 2 Data Showed Rapid Viral Response to VX-222 in Combination with Telaprevir, Pegylated-Interferon and Ribavirin Among People With Hepatitis C BERLIN--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced interim results from an ongoing Phase 2 study (ZENITH) designed to assess the safety and tolerability of 12-week response-guided treatment regimens with its polymerase inhibitor, VX-222, and its protease HCV	View HTML Interim Phase 2 Data Showed Rapid Viral Response to VX-222 in Combination with Telaprevir, Pegylated-Interferon and Ribavirin Among People With Hepatitis C 40.6 KB